Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
There is a growing body of evidence exploring the role of curcumin as a radioprotector
against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor
cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate
cancer patients undergoing radiotherapy.